Related references
Note: Only part of the references are listed.Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment
Ulrike Klein et al.
ANNALS OF HEMATOLOGY (2011)
Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial
Philippe Moreau et al.
BLOOD (2011)
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation
Joaquin Martinez-Lopez et al.
BLOOD (2011)
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma
Sumit Madan et al.
BLOOD (2011)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients
Francesca Gay et al.
BLOOD (2011)
Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy
L. Karlin et al.
BONE MARROW TRANSPLANTATION (2011)
Re-transplantation after bortezomib-based therapy
Curly Morris et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Rapid Early Monoclonal Protein Reduction After Therapy With Bortezomib or Bortezomib and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Myeloma Is Associated With a Longer Time to Progression
Jatin Shah et al.
CANCER (2011)
Treatment of relapsed and refractory multiple myeloma in the era of novel agents
Niels W. C. J. van de Donk et al.
CANCER TREATMENT REVIEWS (2011)
Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone
Jesus F. San-Miguel et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients
T. Guglielmelli et al.
EUROPEAN JOURNAL OF CANCER (2011)
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group
Meral Beksac et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Emerging therapies for the treatment of relapsed or refractory multiple myeloma
Meletios A. Dimopoulos et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Abnormal modulation of cell protective systems in response to ischemic/reperfusion injury is important in the development of mouse sickle cell hepatopathy
Angela Siciliano et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply)
Giuseppe Visani et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma
Bruno Paiva et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
Irene M. Ghobrial et al.
LANCET ONCOLOGY (2011)
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau et al.
LANCET ONCOLOGY (2011)
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
M. A. Dimopoulos et al.
LEUKEMIA (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective
Heinz Ludwig et al.
ONCOLOGIST (2011)
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
Henk M. Lokhorst et al.
BLOOD (2010)
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
Anders Waage et al.
BLOOD (2010)
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
Jean-Luc Harousseau et al.
BLOOD (2010)
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
Frits van Rhee et al.
BLOOD (2010)
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
Sara Bringhen et al.
BLOOD (2010)
CR represents an early index of potential long survival in multiple myeloma
M. Wang et al.
BONE MARROW TRANSPLANTATION (2010)
The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study
Stephen A. Schey et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
The Efficacy and Safety of Lenalidomide Plus Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients With Impaired Renal Function
Meletios Dimopoulos et al.
CANCER (2010)
Meeting the Unmet Needs in Anticoagulant Therapy
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis
Ambuj Kumar et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma
Jean-Luc Harousseau et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations
Bilal Mohty et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
Pierre Wijermans et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents
Asher A. Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
Maria-Victoria Mateos et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma
Henk Lokhorst et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
Meletios A. Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
Marco Ladetto et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo et al.
LANCET (2010)
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
Maria-Victoria Mateos et al.
LANCET ONCOLOGY (2010)
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
Annemiek Broyl et al.
LANCET ONCOLOGY (2010)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2010)
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma
A. Palumbo et al.
LEUKEMIA (2010)
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone
H. Avet-Loiseau et al.
LEUKEMIA (2010)
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies
M. A. Dimopoulos et al.
LEUKEMIA (2010)
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
M. Q. Lacy et al.
LEUKEMIA (2010)
Ultra High-Risk Myeloma
Herve Avet-Loiseau
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2010)
Relapsed Multiple Myeloma
Sagar Lonial
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2010)
Evidence-Based Mini-Review: Treatment Options for Patients with Relapsed/Refractory Myeloma Previously Treated with Novel Agents and High-Dose Chemotherapy and Autologous Stem-Cell Transplantation
Nina Shah et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2010)
Renal Insufficiency and Failure
Meletios A. Dimopoulos et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2010)
Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib
Raman Sood et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
The role of complete response in multiple myeloma
Jean-Luc Harousseau et al.
BLOOD (2009)
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
Stefan Knop et al.
BLOOD (2009)
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma
R. L. Olin et al.
BONE MARROW TRANSPLANTATION (2009)
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program
Joseph R. Mikhael et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
Edward A. Stadtmauer et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials
Jean-Luc Harousseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Relapse/Refractory Myeloma Patient: Potential Treatment Guidelines
Jesus F. San Miguel
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
Cyrille Hulin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure
Andrew Spencer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The use of novel agents in the treatment of relapsed and refractory multiple myeloma
J. P. Laubach et al.
LEUKEMIA (2009)
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
E. Kastritis et al.
LEUKEMIA (2009)
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
M. A. Dimopoulos et al.
LEUKEMIA (2009)
Treatment of Relapsed/Refractory Multiple Myeloma
Efstathios Kastritis et al.
SEMINARS IN HEMATOLOGY (2009)
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma
A. Palumbo et al.
ANNALS OF ONCOLOGY (2008)
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
Michael Wang et al.
BLOOD (2008)
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
Bart Barlogie et al.
BLOOD (2008)
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Antonio Palumbo et al.
BLOOD (2008)
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Bruno Paiva et al.
BLOOD (2008)
Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma
H. de Lavallade et al.
BONE MARROW TRANSPLANTATION (2008)
Impact of early relapse after auto-SCT for multiple myeloma
S. Kumar et al.
BONE MARROW TRANSPLANTATION (2008)
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma
Ruben Niesvizky et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
Juan Jose Lahuerta et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma
Therese M. Conner et al.
CLINICAL LYMPHOMA & MYELOMA (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Recent major improvement in long-term survival of younger patients with multiple myeloma
Hermann Brenner et al.
BLOOD (2008)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo et al.
LEUKEMIA (2008)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
Thierry Facon et al.
LANCET (2007)
Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma
Helgi J. K. van de Velde et al.
HAEMATOLOGICA (2007)
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma:: Combination therapy improves time to progression
Robert Z. Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma
Martin Kropff et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)
P. Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Patterns of survival in multiple myeloma:: A population-based study of patients diagnosed in Sweden from 1973 to 2003
Sigurdur Yngvi Kristinsson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma
Michel Attal et al.
BLOOD (2006)
Prolonged overall survival with second on-demand autologous transplant in multiple myeloma
Francesca Elice et al.
AMERICAN JOURNAL OF HEMATOLOGY (2006)
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled-trial
A Palumbo et al.
LANCET (2006)
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
B Barlogie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma
MH Qazilbash et al.
CANCER (2006)
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the group myelome-autogreffe
J Fermand et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Transplantation salvage therapy for high-risk patients with myeloma in relapse
CK Lee et al.
BONE MARROW TRANSPLANTATION (2002)
Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma
MA Gertz et al.
BONE MARROW TRANSPLANTATION (2000)
Share Paper
